[Treatment of relapsing-remitting multiple sclerosis with recombinant interferon-beta preparations].
Three recombinant interferon-beta preparations, Betaferon (IFN beta-1b) and Avonex and Rebif (INF beta-1a) have been approved for the therapy of relapsing-remitting multiple sclerosis (MS). The results from pharmacokinetic and pharmacodynamic studies with different interferon-beta preparations reflect only in part the mechanisms of action of this substance, because standard assays primarily measure antiviral bioactivity. These studies are often overinterpreted in relation to the therapy of MS. In this article, we critically evaluate the results of pharmacologic studies with respect to the dose-dependent efficacy of different interferon-beta preparations.
Klinische Forschungsgruppe für Multiple Sklerose und Neuroimmunologie, Neurologische Universitätsklinik Würzburg. matthias.maurer@mail.uni-wuerzburg.de
M
M
Mäurer
R
R
Gold
K V
KV
Toyka
P
P
Rieckmann
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005858:Germany; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000494:pharmacology*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000494:pharmacology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a